Total Assets
Rate Of Return$Novo Nordisk AS(NVO.US) The U.S. Food and Drug Administration (FDA) told Novo Nordisk that its weight loss drug Wegovy TV ads were either false or misleading.
The FDA requested in a letter that Novo Nordisk provide a list of similar promotional communications within 15 business days, along with a plan to cease such communications or stop distributing Wegovy.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
